ImmunoMet Therapeutics Raises $5.0 million in a Series B Financing
ImmunoMet Therapeutics, a development stage biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced that the Company has raised $5.0 million in a Series B financing with participation from Intervest, SL Investment, NHN Investment along with the Series A investors Mirae Asset Venture Investments, GNTech and Dr. Sung-wuk Kim, founder, Chairman and CEO of ImmunoMet.
"This financing will fund the Company's Phase 1 clinical study for IM156 and the preclinical studies of our immuno-oncology program that is focused on inhibiting immune suppressor cells. We are enthusiastic about the potential opportunities in our pipeline to provide life-saving medicines for patients, especially those with drug resistant cancers," said Benjamin R. Cowen, Chief Operating Officer of ImmunoMet.
The Company's lead molecule, IM156, an OXPHOS inhibitor, is expected to enter a Phase 1 clinical trial in the second quarter of 2017. IM156 has demonstrated positive in vivo results in resistant brain and lung tumors in preclinical studies.
Additionally, the Company's immuno-oncology program, IM188, is being developed in combination with immunotherapies, including an anti-PD1. The IM188 program is in late stage lead-optimization and has demonstrated tumor regression in a renal cancer model.
Dr. Sung-wuk Kim, CEO of ImmunoMet, said, "In addition to the completion of this Series B round, the Company has made significant progress including the strengthening of our management team, the formation of our world-renowned scientific advisory board, and establishing our headquarters and research and development facilities at JLABS in Houston TX."
This article has been republished from materials provided by ImmunoMet. Note: material may have been edited for length and content. For further information, please contact the cited source.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018